Navigation Links
AACR announces new journal, Cancer Discovery
Date:10/29/2010

PHILADELPHIA The American Association for Cancer Research announces the launch of its newest journal, Cancer Discovery, which will publish high-impact, peer-reviewed articles describing major advances in basic and clinical research. Its unique format will feature game-changing research, review articles, perspectives and commentaries, news, and "Research Watch" summaries of important journal articles. Cancer Discovery is a new addition to the AACR's robust publication program.

Cancer Discovery combines the expertise and experience of founding Editors-in-Chief Lewis C. Cantley, Ph.D., and Jos Baselga, M.D., Ph.D., along with full-time professional editors. Mark W. Landis, Ph.D., has been appointed executive editor.

"Cancer Discovery will make major contributions to the growing body of knowledge and be a touchstone for the diverse professional community in the cancer field," said Cantley.

Baselga added, "Topics will span the spectrum of cancer science and medicine; from the laboratory to the clinic to epidemiologic and prevention studies. This is a vital resource for everyone working on the problem of cancer."

"Facilitating communication and cross-disciplinary interactions in the field by publishing excellent journals is a core mission of the American Association for Cancer Research," said AACR Chief Executive Officer Margaret Foti, Ph.D., M.D. (h.c.). "We are thrilled that Cancer Discovery will provide a new publication outlet that captures the most significant work in the field and inspires thinking that will accelerate the pace of breakthroughs."

Cantley is director of the cancer center and chief of the division of signal transduction at Beth Israel Deaconess Medical Center. He is also professor of systems biology at Harvard Medical School. Cantley's laboratory discovered PI3 Kinase (PI3K) and revealed its role in a pathway that controls cell growth and cell transformation. PI3K is implicated in many cancers as well as in other diseases. As a result, pharmaceutical intervention in the PI3K pathway is being explored.

Baselga is chief of the division of hematology/oncology and associate director of the Massachusetts General Hospital Cancer Center. He is also professor of medicine at Harvard Medical School. Baselga's research focuses on the clinical development of novel, molecular-targeted agents for the therapy of cancer, particularly breast cancer. He conducted the initial clinical trials with the monoclonal antibodies cetuximab and trastuzumab and has been involved in the clinical development of several new agents including pertuzumab and PI3K inhibitors. His main focus in the laboratory and clinic is in the area of novel anti-HER2 agents, in the identification of mechanisms of resistance to anti-HER2 agents.

Landis was previously with Cell Press, most recently as senior editor for the journal Molecular Cell. Landis holds a doctorate in biological chemistry and molecular pharmacology from Harvard University, where his work focused on breast cancer. He has held research and teaching assistantships at Dartmouth College, the University of Massachusetts Medical School and Children's Hospital in Boston.


'/>"/>

Contact: Michele Sharp
michele.sharp@aacr.org
267-646-0622
American Association for Cancer Research
Source:Eurekalert

Related biology news :

1. CIC Announces Upcoming Webinar: Insurance Consumer Expectations; Customer Experience & Self-Service Will Hit New Highs in 2011! The Role eSignatures Will Play in Meeting that Demand
2. ClinOps Announces Appointment of New President and CEO
3. Aware, Inc. Announces Q310 Earnings Conference Call
4. NYSCF announces 2010 NYSCF Investigators
5. Onconova announces FDA agreement of a SPA for a pivotal phase 3 trial of Estybon in MDS
6. Penn Vet announces $100,000 winners of 2010 World Leadership Award and Student Inspiration Awards
7. TERMIS-North America announces speakers for annual event
8. American Society of Agronomy announces the class of 2010 Fellows
9. American Society of Agronomy announces award recipients
10. Biophysical Society announces 2011 society fellows
11. ActiveCare, Inc. Announces Capital Raise Commitment and Balance Sheet Restructuring
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/30/2017)... Trends, opportunities and forecast in this market ... (fingerprint, AFIS, iris recognition, facial recognition, hand geometry, vein ... use industry (government and law enforcement, commercial and retail, ... others), and by region ( North America ... Pacific , and the Rest of the World) ...
(Date:3/27/2017)... , March 27, 2017  Catholic Health Services ... Management Systems Society (HIMSS) Analytics for achieving Stage ... Model sm . In addition, CHS previously earned ... hospitals using an electronic medical record (EMR). ... high level of EMR usage in an outpatient ...
(Date:3/23/2017)... The report "Gesture Recognition and Touchless Sensing Market by ... Global Forecast to 2022", published by MarketsandMarkets, the market is expected to be ... 2017 and 2022. Continue Reading ... ... ...
Breaking Biology News(10 mins):
(Date:10/12/2017)... ... October 12, 2017 , ... ... pharmaceutical and biotechnology industries to improve patient outcomes and quality of life, will ... analytical testing are being attributed to new regulatory requirements for all new drug ...
(Date:10/11/2017)... CA, USA (PRWEB) , ... October 11, 2017 , ... ... to take place on 7th and 8th June 2018 in San Francisco, CA. The ... influencers as well as several distinguished CEOs, board directors and government officials from around ...
(Date:10/11/2017)... , ... October 11, 2017 , ... ... the implantation and pregnancy rates in frozen and fresh in vitro fertilization ... progesterone and maternal age to IVF success. , After comparing the results from ...
(Date:10/10/2017)... ... 2017 , ... Dr. Bob Harman, founder and CEO of VetStem Biopharma, ... The event entitled “Stem Cells and Their Regenerative Powers,” was held on ... DVM, MPVM was joined by two human doctors: Peter B. Hanson, M.D., Chief of ...
Breaking Biology Technology: